We start intraday on 02 Mar 2026 with Bayer AG (BAYN.DE) trading at €41.85 ahead of its earnings report due 04 Mar 2026. BAYN.DE stock faces investor scrutiny after a mixed 2024 and recent rally; volume today is 2,256,333.00 shares and the 50-day average is €41.98. We focus on cash flow, EPS trends and near-term catalysts to frame trading risk and opportunity in Germany (XETRA).

BAYN.DE stock: Earnings preview and market expectation

Bayer reports next on 04 Mar 2026, with markets watching margins and Crop Science guidance. Today the intraday range is €41.46 to €42.52, with previous close €41.85. We expect management to highlight free cash flow and any remediation to net debt.

Financials and key metrics

Bayer shows trailing EPS of -0.20 and a negative P/E of -210.05, reflecting last year’s accounting items. The company has €41,271,635,685.00 market capitalisation and enterprise value €75,012,635,685.00, with price-to-sales 0.90 and price-to-book 1.40. These ratios signal a valuation anchored to cash generation rather than earnings this cycle.

Meyka grade and forecast

Meyka AI rates BAYN.DE with a score out of 100: 68.93 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a near-term target of €49.38, implying 18.01% upside from the current €41.85. Forecasts are model-based projections and not guarantees.

Technical setup and trading context

Short-term momentum is mixed: RSI 42.06 and MACD histogram negative. Bollinger middle band sits at €44.91, with lower band €41.30, suggesting support near current levels. Average volume runs 3,693,602.00 and today’s 2,256,333.00 shares are below average, signalling cautious positioning ahead of results.

Risks, catalysts and sector comparison

Key risks include net debt to EBITDA of 5.53 and a stretched interest coverage of 2.91, which raise sensitivity to operational setbacks. Catalysts are trial readouts, Crop Science seasonality and cost savings. Healthcare peers show mixed performance; sector momentum may help or hurt Bayer depending on clinical and regulatory headlines.

Short-term outlook and price targets

Near-term model-based targets: Meyka monthly €49.38, conservative target €44.00, and downside scenario €35.00 if guidance disappoints. Traders should link earnings beats to free cash flow upgrades and downgrades to margin or litigation updates. For intraday traders, watch €41.30 support and €44.91 resistance.

Final Thoughts

Key takeaways for BAYN.DE stock on 02 Mar 2026: Bayer enters earnings with €41.85 stock price, trailing EPS -0.20, and stretched leverage metrics. Investors should weight free cash flow strength against net debt risks and volatile sentiment in Healthcare. Meyka AI’s forecast model projects €49.38, an implied upside of 18.01% versus today’s price; we present that as a model-based target, not a guarantee. Our grade, 68.93 (B, HOLD), reflects balanced upside potential and financial leverage. For intraday and short-term traders on XETRA, monitor guidance, cash flow commentary, and volume shifts tied to the 04 Mar release. Use conservative position sizing given interest coverage near 2.91 and the negative P/E, and reassess after the earnings call.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.